<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33917673</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Pathway from TDP-43-Related Pathology to Neuronal Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3843</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22083843</ELocationID><Abstract><AbstractText>Transactivation response DNA binding protein 43 kDa (TDP-43) is known to be a pathologic protein in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). TDP-43 is normally a nuclear protein, but affected neurons of ALS or FTLD patients exhibit mislocalization of nuclear TDP-43 and cytoplasmic inclusions. Basic studies have suggested gain-of-neurotoxicity of aggregated TDP-43 or loss-of-function of intrinsic, nuclear TDP-43. It has also been hypothesized that the aggregated TDP-43 functions as a propagation seed of TDP-43 pathology. However, a mechanistic discrepancy between the TDP-43 pathology and neuronal dysfunctions remains. This article aims to review the observations of TDP-43 pathology in autopsied ALS and FTLD patients and address pathways of neuronal dysfunction related to the neuropathological findings, focusing on impaired clearance of TDP-43 and synaptic alterations in TDP-43-related ALS and FTLD. The former may be relevant to intraneuronal aggregation of TDP-43 and exocytosis of propagation seeds, whereas the latter may be related to neuronal dysfunction induced by TDP-43 pathology. Successful strategies of disease-modifying therapy might arise from further investigation of these subcellular alterations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riku</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6493-8976</Identifier><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Aichi 480-1195, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya 744-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seilhean</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuropathology Raymond Escourolle, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re Charles Foix, AP-HP-Sorbonne Universit&#xe9;, F-75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Sorbonne University, F-75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Brain Institute (ICM), Inserm U 1127, CNRS UMR7225, Sorbonne University, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duyckaerts</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuropathology Raymond Escourolle, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re Charles Foix, AP-HP-Sorbonne Universit&#xe9;, F-75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Sorbonne University, F-75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Brain Institute (ICM), Inserm U 1127, CNRS UMR7225, Sorbonne University, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boluda</LastName><ForeName>Susana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8045-2706</Identifier><AffiliationInfo><Affiliation>Department of Neuropathology Raymond Escourolle, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re Charles Foix, AP-HP-Sorbonne Universit&#xe9;, F-75013 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Brain Institute (ICM), Inserm U 1127, CNRS UMR7225, Sorbonne University, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iguchi</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya 744-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishigaki</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9555-0659</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya 744-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0059-3104</Identifier><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Aichi 480-1195, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Aichi 480-1195, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Graduate School of Medicine, Aichi Medical University, Aichi 480-1195, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9453-9311</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya 744-8550, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP20K16586</GrantID><Agency>JSPS KAKENHI</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="Y">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073659" MajorTopicYN="N">Gain of Function Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073658" MajorTopicYN="N">Loss of Function Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">synapse</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33917673</ArticleId><ArticleId IdType="pmc">PMC8068029</ArticleId><ArticleId IdType="doi">10.3390/ijms22083843</ArticleId><ArticleId IdType="pii">ijms22083843</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., D&#xf6;rk T., Zuccato E., Pagani F., Romano M., Baralle F.E. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20:1774&#x2013;1784. doi: 10.1093/emboj/20.7.1774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.7.1774</ArticleId><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B., Miller R., Swash M., Munsat T. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott E.O., Malek A.M., Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb. Clin. Neurol. 2016;138:225&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G., Piccininni M. Amyotrophic lateral sclerosis descriptive epidemiology: The origin of geographic difference. Neuroepidemiology. 2019;52:93&#x2013;103. doi: 10.1159/000493386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000493386</ArticleId><ArticleId IdType="pubmed">30602169</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554. doi: 10.1212/WNL.51.6.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle-Gilchrist I.T., Dick K.M., Patterson K., V&#xe1;zquez Rodr&#xed;quez P., Wehmann E., Wilcox A., Lansdall C.J., Dawson K.E., Wiggins J., Mead S., et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86:1736&#x2013;1743. doi: 10.1212/WNL.0000000000002638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002638</ArticleId><ArticleId IdType="pmc">PMC4854589</ArticleId><ArticleId IdType="pubmed">27037234</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;1014. doi: 10.1212/WNL.0b013e31821103e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>De Boer E.M.J., Orie V.K., Williams T., Baker M.R., De Oliveira H.M., Polvikoski T., Silsby M., Menon P., van den Bos M., Halliday G.M., et al. TDP-43 proteinopathies: A new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry. 2020;92:86&#x2013;95. doi: 10.1136/jnnp-2020-322983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan R.H., Ke Y.D., Ittner L.M., Halliday G.M. ALS/FTLD: Experimental models and reality. Acta Neuropathol. 2017;133:177&#x2013;196. doi: 10.1007/s00401-016-1666-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1666-6</ArticleId><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortob&#xe1;gyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T.G., Buratti E., Baralle F., Morita M., et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Masuda-Suzukake M., Arai T., Hasegawa Y., Akatsu H., Obi T., Yoshida M., Murayama S., Mann D.M., Akiyama H., et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4:124&#x2013;134. doi: 10.1016/j.celrep.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Arai K., Del Tredici K., Toledo J.B., Robinson J.L., Lee E.B., Kuwabara S., Shibuya K., Irwin D.J., Fang L. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128:423&#x2013;437. doi: 10.1007/s00401-014-1299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1299-6</ArticleId><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno Y., Fujita Y., Takatama M., Okamoto K. Comparison of phosphorylated TDP-43-positive inclusions in oculomotor neurons in patients with non-ALS and ALS disorders. J. Neurol. Sci. 2012;315:20&#x2013;25. doi: 10.1016/j.jns.2011.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2011.12.012</ArticleId><ArticleId IdType="pubmed">22257502</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F., Kakita A., Takahashi H., Wakabayashi K. Co-localization of Bunina bodies and TDP-43 inclusions in lower motor neurons in amyotrophic lateral sclerosis. Neuropathology. 2014;34:71&#x2013;76. doi: 10.1111/neup.12044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12044</ArticleId><ArticleId IdType="pubmed">23711197</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K., Mizuno Y., Fujita Y. Bunina bodies in amyotrophic lateral sclerosis. Neuropathology. 2008;28:109&#x2013;115. doi: 10.1111/j.1440-1789.2007.00873.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2007.00873.x</ArticleId><ArticleId IdType="pubmed">18069968</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K.A., Hodges J.R., Snowden J.S., Mackenzie I.R., Neumann M., Mann D.M., Dickson D.W. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122:137&#x2013;153. doi: 10.1007/s00401-011-0839-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0839-6</ArticleId><ArticleId IdType="pmc">PMC3232515</ArticleId><ArticleId IdType="pubmed">21614463</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Neumann M., Baborie A., Sampathu D.M., Du Plessis D., Jaros E., Perry R.H., Trojanowski J.Q., Mann D.M., Lee V.M. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113. doi: 10.1007/s00401-011-0845-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu D.M., Neumann M., Kwong L.K., Chou T.T., Micsenyi M., Truax A., Bruce J., Grossman M., Trojanowski J.Q., Lee V.M. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am. J. Pathol. 2006;169:1343&#x2013;1352. doi: 10.2353/ajpath.2006.060438.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060438</ArticleId><ArticleId IdType="pmc">PMC1780184</ArticleId><ArticleId IdType="pubmed">17003490</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns N.J., Neumann M., Bigio E.H., Holm I.E., Troost D., Hatanpaa K.J., Foong C., White C.L., 3rd, Schneider J.A., Kretzschmar H.A., et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 2007;171:227&#x2013;240. doi: 10.2353/ajpath.2007.070182.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070182</ArticleId><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K.A., Stroh A., Dugger B., Dickson D.W. Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol. 2009;118:349&#x2013;358. doi: 10.1007/s00401-009-0547-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0547-7</ArticleId><ArticleId IdType="pmc">PMC3044602</ArticleId><ArticleId IdType="pubmed">19455346</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T., Seilhean D., Le Ber I., Millecamps S., Sazdovitch V., Kitagawa K., Uchihara T., Duyckaerts C. Amygdala TDP-43 pathology in frontotemporal lobar degeneration and motor neuron disease. J. Neuropathol. Exp. Neurol. 2017;76:800&#x2013;812. doi: 10.1093/jnen/nlx063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx063</ArticleId><ArticleId IdType="pubmed">28859337</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden J., Neary D., Mann D. Frontotemporal lobar degeneration: Clinical and pathological relationships. Acta Neuropathol. 2007;114:31&#x2013;38. doi: 10.1007/s00401-007-0236-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0236-3</ArticleId><ArticleId IdType="pubmed">17569065</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F., Martinez-Lage M., Robinson J., Uryu K., Neumann M., Brandmeir N.J., Xie S.X., Kwong L.K., Elman L., McCluskey L., et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch. Neurol. 2009;66:180&#x2013;189. doi: 10.1001/archneurol.2008.558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.558</ArticleId><ArticleId IdType="pmc">PMC2774117</ArticleId><ArticleId IdType="pubmed">19204154</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Watanabe H., Yoshida M., Tatsumi S., Mimuro M., Iwasaki Y., Katsuno M., Iguchi Y., Masuda M., Senda J., et al. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:172&#x2013;179. doi: 10.1001/jamaneurol.2013.5489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.5489</ArticleId><ArticleId IdType="pubmed">24378564</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Atsuta N., Yoshida M., Tatsumi S., Iwasaki Y., Mimuro M., Watanabe H., Ito M., Senda J., Nakamura R., et al. Differential motor neuron involvement in progressive muscular atrophy: A comparative study with amyotrophic lateral sclerosis. BMJ Open. 2014;4:e005213. doi: 10.1136/bmjopen-2014-005213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2014-005213</ArticleId><ArticleId IdType="pmc">PMC4025414</ArticleId><ArticleId IdType="pubmed">24833696</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H., Arai T., Kametani F., Nonaka T., Yamashita M., Suzukake M., Hosokawa M., Yoshida M., Hatsuta H., Takao M., et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain. 2012;135:3380&#x2013;3391. doi: 10.1093/brain/aws230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws230</ArticleId><ArticleId IdType="pubmed">23035040</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F., Maniecka Z., P&#xe9;rez-Berlanga M., Hruska-Plochan M., Gilhespy L., Hock E.M., Wagner U., Afroz T., Boersema P.J., Barmettler G., et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat. Neurosci. 2019;22:65&#x2013;77. doi: 10.1038/s41593-018-0294-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0294-y</ArticleId><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H., Kleinberger G., Janssens J., Pereson S., Joris G., Cuijt I., Smits V., Ceuterick-de Groote C., Van Broeckhoven C., Kumar-Singh S. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2010;107:3858&#x2013;3863. doi: 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskaran P., Shaw C., Guthrie S. TDP-43 causes neurotoxicity and cytoskeletal dysfunction in primary cortical neurons. PLoS ONE. 2018;13:e0196528. doi: 10.1371/journal.pone.0196528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0196528</ArticleId><ArticleId IdType="pmc">PMC5963761</ArticleId><ArticleId IdType="pubmed">29787572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebstein S.Y., Yagudayeva I., Shneider N.A. Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a TARDBP knock in mouse model of ALS. Cell Rep. 2019;26:364&#x2013;373.e4. doi: 10.1016/j.celrep.2018.12.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.12.045</ArticleId><ArticleId IdType="pubmed">30625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton M.J., Igaz L.M., Wong M.M., Kwong L.K., Trojanowski J.Q., Lee V.M. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008;283:13302&#x2013;13309. doi: 10.1074/jbc.M800342200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L.M., Kwong L.K., Lee E.B., Chen-Plotkin A., Swanson E., Unger T., Malunda J., Xu Y., Winton M.J., Trojanowski J.Q., et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 2011;121:726&#x2013;738. doi: 10.1172/JCI44867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44867</ArticleId><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L.S., Cheng W.C., Chen C.Y., Wu M.C., Wang Y.C., Tseng Y.H., Chuang T.J., Shen C.J. Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons. Acta Neuropathol. Commun. 2019;7:50. doi: 10.1186/s40478-019-0674-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0674-x</ArticleId><ArticleId IdType="pmc">PMC6440020</ArticleId><ArticleId IdType="pubmed">30922385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J., Guerrero E.N., Hegde P.M., Liachko N.F., Wang H., Vasquez V., Gao J., Pandey A., Taylor J.P., Kraemer B.C., et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc. Natl. Acad. Sci. USA. 2019;116:4696&#x2013;4705. doi: 10.1073/pnas.1818415116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1818415116</ArticleId><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Donde A., Sun M., Ling J.P., Braunstein K.E., Pang B., Wen X., Cheng X., Chen L., Wong P.C. Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol. 2019;138:813&#x2013;826. doi: 10.1007/s00401-019-02042-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02042-8</ArticleId><ArticleId IdType="pmc">PMC6802294</ArticleId><ArticleId IdType="pubmed">31332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldi T.K., Ash P.E., Wilson G., Gonzales P., Garrido-Lecca A., Roberts C.M., Dostal V., Gendron T.F., Stein L.D., Blumenthal T., et al. TDP-1, the Caenorhabditis elegans ortholog of TDP-43, limits the accumulation of double-stranded RNA. EMBO J. 2014;33:2947&#x2013;2966. doi: 10.15252/embj.201488740.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201488740</ArticleId><ArticleId IdType="pmc">PMC4282642</ArticleId><ArticleId IdType="pubmed">25391662</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Brettschneider J., Ludolph A.C., Lee V.M., Trojanowski J.Q., Del Tredici K. Amyotrophic lateral sclerosis&#x2014;A model of corticofugal axonal spread. Nat. Rev. Neurol. 2013;9:708&#x2013;714. doi: 10.1038/nrneurol.2013.221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.221</ArticleId><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Toledo J.B., Robinson J.L., Irwin D.J., Grossman M., Suh E., Van Deerlin V.M., Wood E.M., Baek Y., et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Irwin D.J., Grossman M., Robinson J.L., Toledo J.B., Fang L., Van Deerlin V.M., Ludolph A.C., Lee V.M., et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) Acta Neuropathol. 2014;127:423&#x2013;439. doi: 10.1007/s00401-013-1238-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1238-y</ArticleId><ArticleId IdType="pmc">PMC3971993</ArticleId><ArticleId IdType="pubmed">24407427</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Watanabe H., Yoshida M., Mimuro M., Iwasaki Y., Masuda M., Ishigaki S., Katsuno M., Sobue G. Marked involvement of the striatal efferent system in TAR DNA-binding protein 43&#x2009;kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2016;75:801&#x2013;811. doi: 10.1093/jnen/nlw053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlw053</ArticleId><ArticleId IdType="pubmed">27346748</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Watanabe H., Yoshida M., Mimuro M., Iwasaki Y., Masuda M., Ishigaki S., Katsuno M., Sobue G. Pathologic involvement of glutamatergic striatal inputs from the cortices in TAR DNA-binding protein 43&#x2009;kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2017;76:759&#x2013;768. doi: 10.1093/jnen/nlx055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx055</ArticleId><ArticleId IdType="pubmed">28859339</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y. Reappraisal of the anatomical spreading and propagation hypothesis about TDP-43 aggregation in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neuropathology. 2020;40:426&#x2013;435. doi: 10.1111/neup.12644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12644</ArticleId><ArticleId IdType="pubmed">32157757</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Bos M.A.J., Geevasinga N., Higashihara M., Menon P., Vucic S. Pathophysiology and diagnosis of ALS: Insights from advances in neurophysiological techniques. Int. J. Mol. Sci. 2019;20:2818. doi: 10.3390/ijms20112818.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112818</ArticleId><ArticleId IdType="pmc">PMC6600525</ArticleId><ArticleId IdType="pubmed">31185581</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller H.P., Turner M.R., Grosskreutz J., Abrahams S., Bede P., Govind V., Prudlo J., Ludolph A.C., Filippi M., Kassubek J., et al. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2016;87:570&#x2013;579. doi: 10.1136/jnnp-2015-311952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311952</ArticleId><ArticleId IdType="pubmed">26746186</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R., de Reus M.A., Scholtens L.H., van den Berg L.H., van den Heuvel M.P. Simulating disease propagation across white matter connectome reveals anatomical substrate for neuropathology staging in amyotrophic lateral sclerosis. Neuroimage. 2016;124:762&#x2013;769. doi: 10.1016/j.neuroimage.2015.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2015.04.005</ArticleId><ArticleId IdType="pubmed">25869856</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F., Caiazzo G., Corbo D., Piccirillo G., Cristillo V., Femiano C., Ferrantino T., Cirillo M., Monsurr&#xf2; M.R., Esposito F., et al. Microstructural changes across different clinical milestones of disease in amyotrophic lateral sclerosis. PLoS ONE. 2015;10:e0119045. doi: 10.1371/journal.pone.0119045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0119045</ArticleId><ArticleId IdType="pmc">PMC4368555</ArticleId><ArticleId IdType="pubmed">25793718</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthess I., Gorges M., M&#xfc;ller H.P., Lul&#xe9; D., Del Tredici K., Ludolph A.C., Kassubek J. Functional connectivity changes resemble patterns of pTDP-43 pathology in amyotrophic lateral sclerosis. Sci. Rep. 2016;6:38391. doi: 10.1038/srep38391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38391</ArticleId><ArticleId IdType="pmc">PMC5144012</ArticleId><ArticleId IdType="pubmed">27929102</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T., Iijima M., Uchihara T., Ohashi T., Seilhean D., Duyckaerts C., Uchiyama S. TDP-43 pathology progression along the olfactory pathway as a possible substrate for olfactory impairment in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2015;74:547&#x2013;556. doi: 10.1097/NEN.0000000000000198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0000000000000198</ArticleId><ArticleId IdType="pubmed">25933387</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T., Uchihara T., Arai N., Mizutani T., Iwata M. Progression of hippocampal degeneration in amyotrophic lateral sclerosis with or without memory impairment: Distinction from Alzheimer disease. Acta Neuropathol. 2009;117:35&#x2013;44. doi: 10.1007/s00401-008-0447-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0447-2</ArticleId><ArticleId IdType="pubmed">19002475</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedeene L., Van Schoor E., Vandenberghe R., Van Damme P., Poesen K., Thal D.R. Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTLD cases. Acta Neuropathol. Commun. 2019;7:189. doi: 10.1186/s40478-019-0845-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0845-9</ArticleId><ArticleId IdType="pmc">PMC6889626</ArticleId><ArticleId IdType="pubmed">31791419</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S., Xu Y., Restrepo C.R., Kwong L.K., Zhang B., Brown H.J., Lee E.B., Trojanowski J.Q., Lee V.M. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat. Commun. 2018;9:4220. doi: 10.1038/s41467-018-06548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06548-9</ArticleId><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S., Iwata M. Ultrastructural change of synapses of Betz cells in patients with amyotrophic lateral sclerosis. Neurosci. Lett. 1999;268:29&#x2013;32. doi: 10.1016/S0304-3940(99)00374-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(99)00374-2</ArticleId><ArticleId IdType="pubmed">10400070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S., Iwata M. Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 1996;204:53&#x2013;56. doi: 10.1016/0304-3940(96)12314-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(96)12314-4</ArticleId><ArticleId IdType="pubmed">8929976</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge C.M., Sideris D.I., Carroll E., Rotariu S., Salomonsson S., Tzioras M., McKenzie C.A., Smith C., von Arnim C.A.F., Ludolph A.C., et al. Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathol. 2018;135:213&#x2013;226. doi: 10.1007/s00401-017-1797-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1797-4</ArticleId><ArticleId IdType="pmc">PMC5773656</ArticleId><ArticleId IdType="pubmed">29273900</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C., Bassell G.J., Rossoll W. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. Hum. Mol. Genet. 2012;21:3703&#x2013;3718. doi: 10.1093/hmg/dds205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds205</ArticleId><ArticleId IdType="pmc">PMC3406762</ArticleId><ArticleId IdType="pubmed">22641816</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyburn L., Hebron M.L., Smith J., Winston C., Bechara J., Li Z., Lonskaya I., Burns M.P., Harris B.T., Moussa C.E. Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis. J. Neurochem. 2016;139:610&#x2013;623. doi: 10.1111/jnc.13763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13763</ArticleId><ArticleId IdType="pubmed">27507246</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L., McInnes J., Wierda K., Holt M., Herrmann A.G., Jackson R.J., Wang Y.C., Swerts J., Beyens J., Miskiewicz K., et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat. Commun. 2017;8:15295. doi: 10.1038/ncomms15295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15295</ArticleId><ArticleId IdType="pmc">PMC5437271</ArticleId><ArticleId IdType="pubmed">28492240</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli R.C., Jawaid A., Henstridge C.M., Valeri A., Merlini M., Robinson J.L., Lee E.B., Rose J., Appel S., Lee V.M., et al. TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss. Neuron. 2017;95:297&#x2013;308.e6. doi: 10.1016/j.neuron.2017.05.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.05.037</ArticleId><ArticleId IdType="pmc">PMC5519492</ArticleId><ArticleId IdType="pubmed">28669544</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid B., Hruscha A., Hogl S., Banzhaf-Strathmann J., Strecker K., van der Zee J., Teucke M., Eimer S., Hegermann J., Kittelmann M., et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc. Natl. Acad. Sci. USA. 2013;110:4986&#x2013;4991. doi: 10.1073/pnas.1218311110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1218311110</ArticleId><ArticleId IdType="pmc">PMC3612625</ArticleId><ArticleId IdType="pubmed">23457265</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim J.R., Williams L.A., Limone F., Guerra San Juan I., Davis-Dusenbery B.N., Mordes D.A., Burberry A., Steinbaugh M.J., Gamage K.K., Kirchner R., et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Udagawa T., Fujioka Y., Tanaka M., Honda D., Yokoi S., Riku Y., Ibi D., Nagai T., Yamada K., Watanabe H., et al. FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilization. Nat. Commun. 2015;6:7098. doi: 10.1038/ncomms8098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8098</ArticleId><ArticleId IdType="pmc">PMC4479014</ArticleId><ArticleId IdType="pubmed">25968143</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen T., Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy. 2011;7:279&#x2013;296. doi: 10.4161/auto.7.3.14487.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.7.3.14487</ArticleId><ArticleId IdType="pmc">PMC3060413</ArticleId><ArticleId IdType="pubmed">21189453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2011;70:349&#x2013;359. doi: 10.1097/NEN.0b013e3182160690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3182160690</ArticleId><ArticleId IdType="pubmed">21487309</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada S.J., Serio A., Arjun A., Bilican B., Daub A., Ando D.M., Tsvetkov A., Pleiss M., Li X., Peisach D., et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. 2014;10:677&#x2013;685. doi: 10.1038/nchembio.1563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1563</ArticleId><ArticleId IdType="pmc">PMC4106236</ArticleId><ArticleId IdType="pubmed">24974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo M., Lee S., Kim K., Lee S., Kim S.R., Kim H.J. Inhibition of MEK5 suppresses TDP-43 toxicity via the mTOR-independent activation of the autophagy-lysosome pathway. Biochem. Biophys. Res. Commun. 2019;513:925&#x2013;932. doi: 10.1016/j.bbrc.2019.04.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.04.088</ArticleId><ArticleId IdType="pubmed">31005259</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibiger C., Deisel J., Aufschnaiter A., Ambros S., Tereshchenko M., Verheijen B.M., B&#xfc;ttner S., Braun R.J. TDP-43 controls lysosomal pathways thereby determining its own clearance and cytotoxicity. Hum. Mol. Genet. 2018;27:1593&#x2013;1607. doi: 10.1093/hmg/ddy066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy066</ArticleId><ArticleId IdType="pubmed">29474575</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y., Eid L., Parent M., Soucy G., Bareil C., Riku Y., Kawai K., Takagi S., Yoshida M., Katsuno M., et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016;139:3187&#x2013;3201. doi: 10.1093/brain/aww237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww237</ArticleId><ArticleId IdType="pmc">PMC5840881</ArticleId><ArticleId IdType="pubmed">27679482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero D., La Salvia S., Giannini M., Crippa V., Gagliardi S., Bernuzzi S., Diamanti L., Ceroni M., Pansarasa O., Poletti A., et al. Pathological proteins are transported by extracellular vesicles of sporadic amyotrophic lateral sclerosis patients. Front. Neurosci. 2018;12:487. doi: 10.3389/fnins.2018.00487.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00487</ArticleId><ArticleId IdType="pmc">PMC6060258</ArticleId><ArticleId IdType="pubmed">30072868</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P.C., Wu D., Hu C.J., Chen H.Y., Hsieh Y.C., Huang C.C. Exosomal TAR DNA-binding protein-43 and neurofilaments in plasma of amyotrophic lateral sclerosis patients: A longitudinal follow-up study. J. Neurol. Sci. 2020;418:117070. doi: 10.1016/j.jns.2020.117070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117070</ArticleId><ArticleId IdType="pubmed">32836016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Rogaeva E. Motor neuron disease and frontotemporal dementia: Sometimes related, sometimes not. Exp. Neurol. 2014;262:75&#x2013;83. doi: 10.1016/j.expneurol.2013.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.11.006</ArticleId><ArticleId IdType="pubmed">24246281</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith K.R., Damiano J., Franceschetti S., Carpenter S., Canafoglia L., Morbin M., Rossi G., Pareyson D., Mole S.E., Staropoli J.F., et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 2012;90:1102&#x2013;1107. doi: 10.1016/j.ajhg.2012.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.04.021</ArticleId><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Lin S., Staats K.A., Li Y., Chang W.H., Hung S.T., Hendricks E., Linares G.R., Wang Y., Son E.Y., et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 2018;24:313&#x2013;325. doi: 10.1038/nm.4490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4490</ArticleId><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Duyckaerts C., Boluda S., Plu I., Le Ber I., Millecamps S., Salachas F., Yoshida M., Ando T., Brainbank NeuroCEB Neuropathology Network Increased prevalence of granulovacuolar degeneration in C9orf72 mutation. Acta Neuropathol. 2019;138:783&#x2013;793. doi: 10.1007/s00401-019-02028-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02028-6</ArticleId><ArticleId IdType="pubmed">31144027</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S.M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G., Parkinson N.J., Brown J.M., Chakrabarti L., Lloyd S.L., Hummerich H., Nielsen J.E., Hodges J.R., Spillantini M.G., Thusgaard T., et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 2005;37:806&#x2013;808. doi: 10.1038/ng1609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1609</ArticleId><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Schoor E., Koper M.J., Ospitalieri S., Dedeene L., Tom&#xe9; S.O., Vandenberghe R., Brenner D., Otto M., Weishaupt J., Ludolph A.C., et al. Necrosome-positive granulovacuolar degeneration is associated with TDP-43 pathological lesions in the hippocampus of ALS/FTLD cases. Neuropathol. Appl. Neurobiol. 2021;47:328&#x2013;345. doi: 10.1111/nan.12668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12668</ArticleId><ArticleId IdType="pubmed">32949047</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H., Katsuno M., Minamiyama M., Sang C., Pagoulatos G., Angelidis C., Kusakabe M., Yoshiki A., Kobayashi Y., Doyu M., et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci. 2003;23:2203&#x2013;2211. doi: 10.1523/JNEUROSCI.23-06-02203.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-06-02203.2003</ArticleId><ArticleId IdType="pmc">PMC6742038</ArticleId><ArticleId IdType="pubmed">12657679</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo N., Katsuno M., Riku Y., Sobue G. Heat Shock Factor. Springer; Tokyo, Japan: 2016. HSF inhibits the progression of age-related neurodegenerative diseases; pp. 213&#x2013;242.</Citation></Reference><Reference><Citation>Chen H.J., Mitchell J.C., Novoselov S., Miller J., Nishimura A.L., Scotter E.L., Vance C.A., Cheetham M.E., Shaw C.E. The heat shock response plays an important role in TDP-43 clearance: Evidence for dysfunction in amyotrophic lateral sclerosis. Brain. 2016;139:1417&#x2013;1432. doi: 10.1093/brain/aww028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww028</ArticleId><ArticleId IdType="pmc">PMC4845254</ArticleId><ArticleId IdType="pubmed">26936937</ArticleId></ArticleIdList></Reference><Reference><Citation>Orme&#xf1;o F., Hormazabal J., Moreno J., Riquelme F., Rios J., Criollo A., Albornoz A., Alfaro I.E., Budini M. Chaperone mediated autophagy degrades TDP-43 protein and is affected by TDP-43 aggregation. Front. Mol. Neurosci. 2020;13:19. doi: 10.3389/fnmol.2020.00019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00019</ArticleId><ArticleId IdType="pmc">PMC7040037</ArticleId><ArticleId IdType="pubmed">32132902</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Lu S., Gasior K., Singh D., Vazquez-Sanchez S., Tapia O., Toprani D., Beccari M.S., Yates J.R., 3rd, Da Cruz S., et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science. 2021;371:eabb4309. doi: 10.1126/science.abb4309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4309</ArticleId><ArticleId IdType="pubmed">33335017</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Ludolph A.C., Neumann M., Ravits J., Del Tredici K. Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal &#x3b1;-motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:79&#x2013;90. doi: 10.1007/s00401-016-1633-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1633-2</ArticleId><ArticleId IdType="pmc">PMC5209403</ArticleId><ArticleId IdType="pubmed">27757524</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordana M.T., Piccinini M., Grifoni S., De Marco G., Vercellino M., Magistrello M., Pellerino A., Buccinn&#xe0; B., Lupino E., Rinaudo M.T. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 2010;20:351&#x2013;360. doi: 10.1111/j.1750-3639.2009.00284.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2009.00284.x</ArticleId><ArticleId IdType="pubmed">19338576</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L., Pozzi S., Castelnovo M., Basso M., Estevez A.G., Fumagalli S., De Simoni M.G., Castellaneta V., Bigini P., Restelli E., et al. Targeting extracellular cyclophilin A reduces neuroinflammation and extends survival in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2017;37:1413&#x2013;1427. doi: 10.1523/JNEUROSCI.2462-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2462-16.2016</ArticleId><ArticleId IdType="pmc">PMC6705677</ArticleId><ArticleId IdType="pubmed">28011744</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P., Risse E., Tyzack G.E., Mitchell J.S., Taha D.M., Chen Y.R., Newcombe J., Collinge J., Sidle K., Patani R. Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain. 2020;143:430&#x2013;440. doi: 10.1093/brain/awz419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz419</ArticleId><ArticleId IdType="pmc">PMC7009461</ArticleId><ArticleId IdType="pubmed">32040555</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller K.J., Restrepo C.R., Khan T., Dominique M.A., Fang T.C., Canter R.G., Roberts C.J., Miller K.R., Ransohoff R.M., Trojanowski J.Q., et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat. Neurosci. 2018;21:329&#x2013;340. doi: 10.1038/s41593-018-0083-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0083-7</ArticleId><ArticleId IdType="pmc">PMC5857237</ArticleId><ArticleId IdType="pubmed">29463850</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRocca T.J., Mariani A., Watkins L.R., Link C.D. TDP-43 knockdown causes innate immune activation via protein kinase R in astrocytes. Neurobiol. Dis. 2019;132:104514. doi: 10.1016/j.nbd.2019.104514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104514</ArticleId><ArticleId IdType="pmc">PMC6834892</ArticleId><ArticleId IdType="pubmed">31229690</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips A.M., Gross S.K., Williams T., Tuteja A., Sherman A., Ko M., Jeong Y.H., Wong P.C., Maragakis N.J. Altered astrocytic expression of TDP-43 does not influence motor neuron survival. Exp. Neurol. 2013;250:250&#x2013;259. doi: 10.1016/j.expneurol.2013.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.10.004</ArticleId><ArticleId IdType="pubmed">24120466</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K.A., Martin P.R., Weigand S.D., Tosakulwong N., Buciuc M., Murray M.E., Petrucelli L., Senjem M.L., Spychalla A.J., Knopman D.S., et al. Protein contributions to brain atrophy acceleration in Alzheimer&#x2019;s disease and primary age-related tauopathy. Brain. 2020;143:3463&#x2013;3476. doi: 10.1093/brain/awaa299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa299</ArticleId><ArticleId IdType="pmc">PMC7719030</ArticleId><ArticleId IdType="pubmed">33150361</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom&#xe9; S.O., Vandenberghe R., Ospitalieri S., Van Schoor E., Tousseyn T., Otto M., von Arnim C.A.F., Thal D.R. Distinct molecular patterns of TDP-43 pathology in Alzheimer&#x2019;s disease: Relationship with clinical phenotypes. Acta Neuropathol. Commun. 2020;8:61. doi: 10.1186/s40478-020-00934-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00934-5</ArticleId><ArticleId IdType="pmc">PMC7189555</ArticleId><ArticleId IdType="pubmed">32349792</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S., Sanchez-Contreras M., Josephs K.A., Uitti R.J., Graff-Radford N., van Gerpen J.A., Cheshire W.P., Wszolek Z.K., Rademakers R., Dickson D.W. Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov. Disord. 2017;32:246&#x2013;255. doi: 10.1002/mds.26809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26809</ArticleId><ArticleId IdType="pmc">PMC5933946</ArticleId><ArticleId IdType="pubmed">28009087</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S., Kouri N., Walton R.L., Ebbert M.T.W., Josephs K.A., Litvan I., Graff-Radford N., Ahlskog J.E., Uitti R.J., van Gerpen J.A., et al. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: A distinct clinicopathologic subtype. Acta Neuropathol. 2018;136:389&#x2013;404. doi: 10.1007/s00401-018-1878-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1878-z</ArticleId><ArticleId IdType="pmc">PMC6309287</ArticleId><ArticleId IdType="pubmed">29926172</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese K.E., Walker L., Erskine D., Thomas A.J., McKeith I.G., Attems J. TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with Lewy bodies and ageing. Brain Pathol. 2017;27:472&#x2013;479. doi: 10.1111/bpa.12424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12424</ArticleId><ArticleId IdType="pmc">PMC8029292</ArticleId><ArticleId IdType="pubmed">27495267</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki N., Murray M.E., Ogaki K., Fujioka S., Rutherford N.J., Rademakers R., Ross O.A., Dickson D.W. Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathol. 2015;129:53&#x2013;64. doi: 10.1007/s00401-014-1358-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1358-z</ArticleId><ArticleId IdType="pmc">PMC4282950</ArticleId><ArticleId IdType="pubmed">25367383</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H., Uryu K., Robinson J., Xie S.X., Hurtig H., Duda J.E., Arnold S.E., Siderowf A., Grossman M., Leverenz J.B., et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114:221&#x2013;229. doi: 10.1007/s00401-007-0261-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0261-2</ArticleId><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S., Iseki E., Yamamoto R., Minegishi M., Hino H., Fujisawa K., Togo T., Katsuse O., Uchikado H., Furukawa Y., et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284&#x2013;294. doi: 10.1016/j.brainres.2007.09.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.048</ArticleId><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C., Lin W.L., Ahmed Z., Personett D., Davies P., Duara R., Graff-Radford N.R., Hutton M.L., Dickson D.W. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann. Neurol. 2007;61:435&#x2013;445. doi: 10.1002/ana.21154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21154</ArticleId><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H., Kara E., Bandopadhyay R., Hardy J., Holton J., Xiromerisiou G., Lees A., Houlden H., Revesz T. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT. Neurobiol Aging. 2013;34:2889.e5&#x2013;2889.e9. doi: 10.1016/j.neurobiolaging.2013.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.04.011</ArticleId><ArticleId IdType="pmc">PMC3906605</ArticleId><ArticleId IdType="pubmed">23664753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenney K., Iacono D., Edlow B.L., Katz D.I., Diaz-Arrastia R., Dams-O&#x2019;Connor K., Daneshvar D.H., Stevens A., Moreau A.L., Tirrell L.S., et al. Dementia after moderate-severe traumatic brain injury: Coexistence of multiple proteinopathies. J. Neuropathol. Exp. Neurol. 2018;77:50&#x2013;63. doi: 10.1093/jnen/nlx101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx101</ArticleId><ArticleId IdType="pmc">PMC5939622</ArticleId><ArticleId IdType="pubmed">29155947</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P.T., Dickson D.W., Trojanowski J.Q., Jack C.R., Boyle P.A., Arfanakis K., Rademakers R., Alafuzoff I., Attems J., Brayne C., et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report. Brain. 2019;142:1503&#x2013;1527. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson J.L., Yan N., Caswell C., Xie S.X., Suh E., Van Deerlin V.M., Gibbons G., Irwin D.J., Grossman M., Lee E.B., et al. Primary tau pathology, not copathology, correlates with clinical symptoms in PSP and CBD. J. Neuropathol. Exp. Neurol. 2020;79:296&#x2013;304. doi: 10.1093/jnen/nlz141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlz141</ArticleId><ArticleId IdType="pmc">PMC7036659</ArticleId><ArticleId IdType="pubmed">31999351</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C., Braak H., Brion J.P., Bu&#xe9;e L., Del Tredici K., Goedert M., Halliday G., Neumann M., Spillantini M.G., Tolnay M., et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129:749&#x2013;756. doi: 10.1007/s00401-015-1390-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1390-7</ArticleId><ArticleId IdType="pmc">PMC4405349</ArticleId><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens C.H., Guthrie N.J., van Roijen M., Halliday G.M., Ooi L. Increased tau phosphorylation in motor neurons from clinically pure sporadic amyotrophic lateral sclerosis patients. J. Neuropathol. Exp. Neurol. 2019;78:605&#x2013;614. doi: 10.1093/jnen/nlz041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlz041</ArticleId><ArticleId IdType="pmc">PMC7967836</ArticleId><ArticleId IdType="pubmed">31131395</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrouzi R., Liu X., Wu D., Robinson A.C., Tanaguchi-Watanabe S., Rollinson S., Shi J., Tian J., Hamdalla H.H., Ealing J., et al. Pathological tau deposition in motor neurone disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. Acta Neuropathol. Commun. 2016;4:33. doi: 10.1186/s40478-016-0301-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0301-z</ArticleId><ArticleId IdType="pmc">PMC4818389</ArticleId><ArticleId IdType="pubmed">27036121</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek K.F., Murray M.E., Rutherford N.J., Castanedes-Casey M., DeJesus-Hernandez M., Liesinger A.M., Baker M.C., Boylan K.B., Rademakers R., Dickson D.W. Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol. 2013;125:289&#x2013;302. doi: 10.1007/s00401-012-1048-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1048-7</ArticleId><ArticleId IdType="pmc">PMC3551994</ArticleId><ArticleId IdType="pubmed">23053135</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson A.C., Thompson J.C., Weedon L., Rollinson S., Pickering-Brown S., Snowden J.S., Davidson Y.S., Mann D.M. No interaction between tau and TDP-43 pathologies in either frontotemporal lobar degeneration or motor neurone disease. Neuropathol. Appl. Neurobiol. 2014;40:844&#x2013;854. doi: 10.1111/nan.12155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12155</ArticleId><ArticleId IdType="pubmed">24861427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimuro M., Yoshida M., Kuzuhara S., Kokubo Y. Amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Hohara focus of the Kii Peninsula: A multiple proteinopathy? Neuropathology. 2018;38:98&#x2013;107. doi: 10.1111/neup.12434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12434</ArticleId><ArticleId IdType="pubmed">29063640</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen B.M., Morimoto S., Sasaki R., Oyanagi K., Kokubo Y., Kuzuhara S., van Leeuwen F.W. Expression of mutant ubiquitin and proteostasis impairment in Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex brains. J. Neuropathol. Exp. Neurol. 2020;79:902&#x2013;907. doi: 10.1093/jnen/nlaa056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlaa056</ArticleId><ArticleId IdType="pubmed">32647880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S., Riku Y., Fujioka Y., Endo K., Iwade N., Kawai K., Ishibashi M., Yokoi S., Katsuno M., Watanabe H., et al. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases. Brain. 2020;143:2398&#x2013;2405. doi: 10.1093/brain/awaa196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa196</ArticleId><ArticleId IdType="pubmed">32770214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S., Fujioka Y., Okada Y., Riku Y., Udagawa T., Honda D., Yokoi S., Endo K., Ikenaka K., Takagi S., et al. Altered tau isoform ratio caused by loss of FUS and SFPQ function leads to FTLD-like phenotypes. Cell Rep. 2017;18:1118&#x2013;1131. doi: 10.1016/j.celrep.2017.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.01.013</ArticleId><ArticleId IdType="pubmed">28147269</ArticleId></ArticleIdList></Reference><Reference><Citation>White M.A., Kim E., Duffy A., Adalbert R., Phillips B.U., Peters O.M., Stephenson J., Yang S., Massenzio F., Lin Z., et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 2018;21:552&#x2013;563. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama J.S., Karch C.M., Fan C.C., Bonham L.W., Kouri N., Ross O.A., Rademakers R., Kim J., Wang Y., H&#xf6;glinger G.U., et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 2017;133:825&#x2013;837. doi: 10.1007/s00401-017-1693-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1693-y</ArticleId><ArticleId IdType="pmc">PMC5429027</ArticleId><ArticleId IdType="pubmed">28271184</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., Wen N., Fan C.C., Yokoyama J.S., Kouri N., Ross O.A., H&#xf6;glinger G., M&#xfc;ller U., Ferrari R., Hardy J., et al. Selective genetic overlap between amyotrophic lateral sclerosis and diseases of the frontotemporal dementia spectrum. JAMA Neurol. 2018;75:860&#x2013;875. doi: 10.1001/jamaneurol.2018.0372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0372</ArticleId><ArticleId IdType="pmc">PMC6043387</ArticleId><ArticleId IdType="pubmed">29630712</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali C.P., Patino M., Tai Y.K., Ho W.Y., McLean C.A., Morris C.M., Seeley W.W., Miller B.L., Gaig C., Vonsattel J.P.G., et al. C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathol. 2019;138:795&#x2013;811. doi: 10.1007/s00401-019-02045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02045-5</ArticleId><ArticleId IdType="pmc">PMC6802287</ArticleId><ArticleId IdType="pubmed">31327044</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K., Nakashima-Yasuda H., Forman M.S., Kwong L.K., Clark C.M., Grossman M., Miller B.L., Kretzschmar H.A., Lee V.M., Trojanowski J.Q., et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J. Neuropathol. Exp. Neurol. 2008;67:555&#x2013;564. doi: 10.1097/NEN.0b013e31817713b5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713b5</ArticleId><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>